fluorouracil has been researched along with Neoplasms, Squamous Cell in 38 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Neoplasms, Squamous Cell: Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of concurrent oral capecitabine with accelerated hypofractionated radical radiotherapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN)." | 9.15 | Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study. ( Birzgalis, A; Homer, J; Jegannathen, A; Lee, L; Mais, K; Ryder, WD; Slevin, N; Sykes, A; Yap, B, 2011) |
| "To evaluate the efficacy of concurrent oral capecitabine with accelerated hypofractionated radical radiotherapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN)." | 5.15 | Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study. ( Birzgalis, A; Homer, J; Jegannathen, A; Lee, L; Mais, K; Ryder, WD; Slevin, N; Sykes, A; Yap, B, 2011) |
| "Patients with advanced head and neck cancer who were treated only with hyperfractionated irradiation received 125 cGy twice daily, for a total of 7500 cGy." | 2.69 | Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. ( Albers, ME; Brizel, DM; Fisher, SR; George, SL; Hars, V; Huang, AT; Prosnitz, LR; Richtsmeier, WJ; Scher, RL, 1998) |
| " Individualized 5-FU dosing to obtain higher 5-FU plasma concentrations may be indicated." | 2.68 | Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. ( Athanasiadis, I; Dolan, ME; Haraf, DJ; Kies, MS; Kozloff, M; Malone, D; Mick, R; Ratain, MJ; Vokes, EE; Weichselbaum, RR, 1996) |
| "Topical treatment of skin cancer may therefore be more appropriate in certain instances." | 2.66 | Topical treatments for skin cancer. ( Boyle, GM; Cullen, JK; Parsons, PG; Simmons, JL, 2020) |
| "The majority of the head and neck cancers are squamous cell carcinomas, which commonly overexpress the EGF receptor (EGFR)." | 2.47 | Cetuximab in the treatment of squamous cell carcinoma of the head and neck. ( Specenier, P; Vermorken, JB, 2011) |
| "Although a decrease in distant metastases has frequently been observed, an improvement in survival from induction has been difficult to demonstrate." | 2.43 | Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? ( Adelstein, DJ; Leblanc, M, 2006) |
| "5 fluorouracil therapy was terminated and the patients were shifted to interferon therapy subsequently." | 1.51 | Severe necrotising inflammatory skin reaction to topical 5-fluorouracil. ( Gokhale, NS, 2019) |
| "Ten patients had disease progression." | 1.38 | Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer. ( Bi, CP; Chang, TH; Chen, MK; Lai, GM; Lin, JT; Liu, MT; Wang, JW, 2012) |
| "Topical 5-FU, as a sole or combined therapy, must be considered a long-term safe and effective treatment for patients affected by OSSN." | 1.37 | Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study. ( Alemany-Rubio, E; Lazzarini, D; Midena, E; Parrozzani, R; Urban, F, 2011) |
| "Furthermore, HNSCC-driven squamospheres appeared to be chemoresistant to cisplatin, 5-fluorouracil (FU), paclitaxel and doxetaxel, and showed increased levels of ABCG2, one of the ATP-binding cassette (ABC) transporters." | 1.37 | Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. ( Cha, YY; Jin, X; Kim, H; Kim, SH; Lim, YC; Oh, SY, 2011) |
| "The growing number of patients with head and neck cancer is a reason to search for new effective treatment strategies." | 1.36 | [Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results]. ( Chilimoniuk, M; Maksimowicz, T; Olszewska, E, 2010) |
| "77." | 1.33 | Osteoprotegerin and bone mass in squamous cell head and neck cancer patients. ( Hernández, JL; Macías, JG; Olmos, JM; Rivera, F; Valero, C; Vega, ME, 2006) |
| "Nine (18%) have died of anal cancer." | 1.32 | Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost. ( Melcher, AA; Sebag-Montefiore, D, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.26) | 18.2507 |
| 2000's | 16 (42.11) | 29.6817 |
| 2010's | 18 (47.37) | 24.3611 |
| 2020's | 2 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Ko, JC | 1 |
| Chen, JC | 1 |
| Wei, CL | 1 |
| Liu, LL | 1 |
| Chien, CC | 1 |
| Huang, IH | 1 |
| Hsieh, JM | 1 |
| Chiang, CS | 1 |
| Tseng, PY | 1 |
| Cheng, HH | 1 |
| Tsao, YC | 1 |
| Lin, YW | 1 |
| Cullen, JK | 1 |
| Simmons, JL | 1 |
| Parsons, PG | 1 |
| Boyle, GM | 1 |
| Gokhale, NS | 1 |
| Fujimoto, Y | 1 |
| Nakashima, Y | 1 |
| Sasaki, S | 1 |
| Jogo, T | 1 |
| Hirose, K | 1 |
| Edahiro, K | 1 |
| Korehisa, S | 1 |
| Taniguchi, D | 1 |
| Kudou, K | 1 |
| Nakaji, YU | 1 |
| Nakanishi, R | 1 |
| Ando, K | 1 |
| Saeki, H | 1 |
| Oki, E | 1 |
| Fujiwara, M | 1 |
| Oda, Y | 1 |
| Maehara, Y | 1 |
| Li, B | 1 |
| Hong, P | 1 |
| Zheng, CC | 1 |
| Dai, W | 1 |
| Chen, WY | 1 |
| Yang, QS | 1 |
| Han, L | 1 |
| Tsao, SW | 1 |
| Chan, KT | 1 |
| Lee, NPY | 1 |
| Law, S | 1 |
| Xu, LY | 1 |
| Li, EM | 1 |
| Chan, KW | 1 |
| Qin, YR | 1 |
| Guan, XY | 1 |
| Lung, ML | 1 |
| He, QY | 1 |
| Xu, WW | 1 |
| Cheung, AL | 1 |
| Kim, S | 1 |
| Jary, M | 1 |
| Mansi, L | 1 |
| Benzidane, B | 1 |
| Cazorla, A | 1 |
| Demarchi, M | 1 |
| Nguyen, T | 1 |
| Kaliski, A | 1 |
| Delabrousse, E | 1 |
| Bonnetain, F | 1 |
| Letondal, P | 1 |
| Bosset, JF | 1 |
| Valmary-Degano, S | 1 |
| Borg, C | 1 |
| Rodriguez, CP | 1 |
| Adelstein, DJ | 4 |
| Rybicki, LA | 2 |
| Saxton, JP | 1 |
| Lorenz, RR | 1 |
| Wood, BG | 2 |
| Strome, M | 2 |
| Esclamado, RM | 2 |
| Lavertu, P | 2 |
| Carroll, MA | 2 |
| Sepulveda, R | 1 |
| Pe'er, J | 1 |
| Midena, E | 2 |
| Seregard, S | 1 |
| Dua, HS | 1 |
| Singh, AD | 1 |
| Clavel, S | 1 |
| Fortin, B | 1 |
| Després, P | 1 |
| Donath, D | 1 |
| Soulières, D | 1 |
| Khaouam, N | 1 |
| Charpentier, D | 1 |
| Bélair, M | 1 |
| Guertin, L | 1 |
| Nguyen-Tan, PF | 1 |
| Parrozzani, R | 1 |
| Lazzarini, D | 1 |
| Alemany-Rubio, E | 1 |
| Urban, F | 1 |
| Has, C | 1 |
| Burger, B | 1 |
| Volz, A | 1 |
| Kohlhase, J | 1 |
| Bruckner-Tuderman, L | 1 |
| Itin, P | 1 |
| Jegannathen, A | 1 |
| Mais, K | 1 |
| Sykes, A | 1 |
| Lee, L | 1 |
| Yap, B | 1 |
| Birzgalis, A | 1 |
| Homer, J | 1 |
| Ryder, WD | 1 |
| Slevin, N | 1 |
| Kogashiwa, Y | 1 |
| Yamauchi, K | 1 |
| Nagafuji, H | 1 |
| Matsuda, T | 1 |
| Tsubosaka, T | 1 |
| Karaho, T | 1 |
| Maruyama, T | 1 |
| Kohno, N | 1 |
| Wisniewska-Jarosinska, M | 1 |
| Sliwinski, T | 1 |
| Kasznicki, J | 1 |
| Kaczmarczyk, D | 1 |
| Krupa, R | 1 |
| Bloch, K | 1 |
| Drzewoski, J | 1 |
| Chojnacki, J | 1 |
| Blasiak, J | 1 |
| Morawiec-Sztandera, A | 1 |
| Lim, YC | 1 |
| Oh, SY | 1 |
| Cha, YY | 1 |
| Kim, SH | 1 |
| Jin, X | 1 |
| Kim, H | 1 |
| Rudkin, AK | 1 |
| Muecke, JS | 1 |
| Chilimoniuk, M | 1 |
| Olszewska, E | 1 |
| Maksimowicz, T | 1 |
| Specenier, P | 1 |
| Vermorken, JB | 3 |
| Guigay, J | 1 |
| Mesia, R | 1 |
| Trigo, JM | 1 |
| Keilholz, U | 1 |
| Kerber, A | 1 |
| Bethe, U | 1 |
| Picard, M | 1 |
| Brummendorf, TH | 1 |
| Lin, JT | 1 |
| Lai, GM | 1 |
| Chang, TH | 1 |
| Liu, MT | 1 |
| Bi, CP | 1 |
| Wang, JW | 1 |
| Chen, MK | 1 |
| Endrizzi, B | 1 |
| Ahmed, RL | 1 |
| Ray, T | 1 |
| Dudek, A | 1 |
| Lee, P | 1 |
| Li, Y | 1 |
| Adams, GL | 1 |
| Wagner, H | 1 |
| Kish, JA | 1 |
| Ensley, JF | 1 |
| Schuller, DE | 1 |
| Forastiere, AA | 2 |
| Gilbert, J | 1 |
| Melcher, AA | 1 |
| Sebag-Montefiore, D | 1 |
| McHam, SA | 1 |
| Schrijvers, D | 1 |
| Van Herpen, C | 1 |
| Kerger, J | 1 |
| Joosens, E | 1 |
| Van Laer, C | 1 |
| Awada, A | 1 |
| Van den Weyngaert, D | 1 |
| Nguyen, H | 1 |
| Le Bouder, C | 1 |
| Castelijns, JA | 1 |
| Kaanders, J | 1 |
| De Mulder, P | 1 |
| Pignon, JP | 1 |
| Syz, N | 1 |
| Posner, M | 1 |
| Olivares, R | 1 |
| Le Lann, L | 1 |
| Yver, A | 1 |
| Dunant, A | 1 |
| Lewin, F | 1 |
| Dalley, DN | 1 |
| Paccagnella, A | 1 |
| Taylor, SG | 1 |
| Domenge, C | 1 |
| Bourhis, J | 1 |
| Mazumdar, M | 1 |
| Stone, DU | 1 |
| Butt, AL | 1 |
| Chodosh, J | 1 |
| Sarbia, M | 1 |
| Stahl, M | 1 |
| von Weyhern, C | 1 |
| Weirich, G | 1 |
| Pühringer-Oppermann, F | 1 |
| Tishler, RB | 1 |
| Posner, MR | 1 |
| Norris, CM | 1 |
| Mahadevan, A | 1 |
| Sullivan, C | 1 |
| Goguen, L | 1 |
| Wirth, LJ | 1 |
| Costello, R | 1 |
| Case, M | 1 |
| Stowell, S | 1 |
| Sammartino, D | 1 |
| Busse, PM | 1 |
| Haddad, RI | 1 |
| Leblanc, M | 1 |
| Valero, C | 1 |
| Olmos, JM | 1 |
| Rivera, F | 1 |
| Hernández, JL | 1 |
| Vega, ME | 1 |
| Macías, JG | 1 |
| Itoh, Y | 1 |
| Fuwa, N | 1 |
| Ijichi, K | 1 |
| Adachi, M | 1 |
| Hasegawa, Y | 1 |
| Ogawa, T | 1 |
| Nakamura, H | 1 |
| Kudoh, A | 1 |
| Yasui, Y | 1 |
| Murakami, S | 1 |
| Ishizaki, K | 1 |
| Weinberg, JM | 1 |
| Vokes, EE | 1 |
| Mick, R | 1 |
| Kies, MS | 1 |
| Dolan, ME | 1 |
| Malone, D | 1 |
| Athanasiadis, I | 1 |
| Haraf, DJ | 1 |
| Kozloff, M | 1 |
| Weichselbaum, RR | 1 |
| Ratain, MJ | 1 |
| Brizel, DM | 1 |
| Albers, ME | 1 |
| Fisher, SR | 1 |
| Scher, RL | 1 |
| Richtsmeier, WJ | 1 |
| Hars, V | 1 |
| George, SL | 1 |
| Huang, AT | 1 |
| Prosnitz, LR | 1 |
| Knowling, M | 1 |
| Browman, G | 1 |
| Siu, L | 1 |
| Khoo, K | 1 |
| Cooke, A | 1 |
| Tannock, I | 1 |
| Klaassen, D | 1 |
| Cripps, C | 1 |
| Goss, G | 1 |
| Matthews, S | 1 |
| Clarke, R | 1 |
| Seymour, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma.[NCT02402842] | Phase 2 | 70 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia Induced by Targeted Therapy and Immunotherapy Combination Treatment[NCT04896528] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-06-06 | Recruiting | ||
| A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients[NCT05590650] | Phase 1 | 21 participants (Actual) | Interventional | 2018-07-07 | Completed | ||
| Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer[NCT03998696] | Phase 4 | 60 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339] | Phase 1 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer[NCT02945631] | 43 participants (Actual) | Interventional | 2016-04-25 | Active, not recruiting | |||
| The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer[NCT01706939] | Phase 3 | 23 participants (Actual) | Interventional | 2012-09-01 | Active, not recruiting | ||
| Observational Study on the Investigation of the Molecular Mechanism and Clinical Significance of the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family.[NCT01927354] | 100 participants (Anticipated) | Observational | 2012-12-31 | Recruiting | |||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Oropharyngeal Cancers[NCT00797446] | 10 participants (Actual) | Observational | 2007-09-30 | Terminated (stopped due to Slow enrollment, feasibility issues) | |||
| The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients[NCT01349309] | 26 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Concurrent Angiogenic and EGFR Blockade in Conjunction With Curative Intent Chemoradiation for Locally Advanced Head and Neck Cancer[NCT00140556] | Early Phase 1 | 28 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Primary Surgery Vs Primary Chemoradiation for Oropharyngeal Cancer (Scope Trial) - A Phase II/III Integrated Design Randomized Control Trial[NCT05144100] | Phase 2/Phase 3 | 498 participants (Anticipated) | Interventional | 2021-12-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy. (NCT01706939)
Timeframe: at 5 years
| Intervention | biomarkers (Number) |
|---|---|
| Reduced Dose Radiation | 0 |
| Standard Dose Radiation | 0 |
MDADI is a questionnaire of 20 questions and contains a global subscale, and three other categories of questions (emotional, functional, and physical). The scores are summed and a mean score is calculated. This mean score was multiplied by 20 to obtain a score, with a range of 0 (extremely low functioning) to 100 (high functioning). Thus, a higher MDADI score represented better day-to-day functioning and better QOL. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | -8.12 |
| Standard Dose Radiation | -8.93 |
XQ is a nine questions survey developed specifically for xerostomia symptoms. The scores are summed and a mean score is calculated on a scale of 0 (low xerostomia interference) to 10 (high xerostomia interference). A lower or negative score reflects a better quality of life compared to baseline. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | 2.18 |
| Standard Dose Radiation | 4.38 |
Number of participants with acute toxicity treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 3 |
| Standard Dose Radiation | 1 |
Local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
Overall Survival (OS) 5 years treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
The EORTC Head and Neck module was specifically designed and validated for head and neck cancer patients. This 35-item questionnaire contains 7 symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), 6 single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and 5 items about the additional use of pain medicine, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, and divided into respective sub-scores of global health (GHS), functional (FS), and symptom scale (SS). Subscales from 0-100. A high score on global health and functional scale represents a better level of functioning, whereas a high score on a symptom scale and head and neck module indicates more severe symptoms. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| EORTC GHS | EORTC FS | EORTC SS | EORTC HN | |
| Reduced Dose Radiation | 5.95 | 5.14 | -3.91 | -2.80 |
| Standard Dose Radiation | -30.56 | -6.33 | 14.97 | 8.97 |
"MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS) MDASI Head and Neck is a site-specific MDASI module which includes the core MDASI 13 symptom severity items (SS) and 6 symptom interference items (SI), alongside 9 items relevant to head and neck cancer. The scores are summed and a mean score is calculated on a scale of 0 (low severity or interference) to 10 (high severity or complete interference). In order to calculate the mean score, a majority of the subscale's items must have been completed.~A lower or negative score reflects a better quality of life compared to baseline." (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MDASI-HN SI | MDASI-HN SS | |
| Reduced Dose Radiation | 0.64 | 0.52 |
| Standard Dose Radiation | 1.56 | 1.48 |
Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 and 5 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| at 3 years | at 5 years | |
| Reduced Dose Radiation | 10 | 10 |
| Standard Dose Radiation | 7 | 7 |
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
Complete response (resolution) of tumor on clinical exam. (NCT00140556)
Timeframe: Within 30 days of completing RT
| Intervention | Participants (Number) |
|---|---|
| Entire Study Population | 25 |
8 reviews available for fluorouracil and Neoplasms, Squamous Cell
| Article | Year |
|---|---|
Topical treatments for skin cancer.
Topics: Administration, Cutaneous; Antineoplastic Agents; Carcinoma, Basal Cell; Clinical Trials as Topic; D | 2020 |
Chemoradiotherapy for Solitary Skeletal Muscle Metastasis from Oesophageal Cancer: Case Report and Brief Literature Review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous | 2017 |
Topical chemotherapy for ocular surface squamous neoplasia: current status.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2010 |
Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2011 |
Organ preservation trials for laryngeal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2002 |
Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clini | 2004 |
Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2006 |
Topical therapy for actinic keratoses: current and evolving therapies.
Topics: Administration, Cutaneous; Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinom | 2006 |
9 trials available for fluorouracil and Neoplasms, Squamous Cell
| Article | Year |
|---|---|
Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Carcinoma, Squamous Cell; Com | 2011 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin | 2010 |
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docet | 2004 |
Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carb | 2006 |
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorour | 1996 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada | 2001 |
21 other studies available for fluorouracil and Neoplasms, Squamous Cell
| Article | Year |
|---|---|
Downregulation of p38 MAPK Activation and Radiation-Sensitive 52 Expression Enhances 5-Fluorouracil and Erlotinib-Induced Cytotoxicity in Human Lung Squamous Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Down-Regulation; Erlotinib Hydrochloride; Fl | 2021 |
Severe necrotising inflammatory skin reaction to topical 5-fluorouracil.
Topics: Administration, Ophthalmic; Antimetabolites, Antineoplastic; Conjunctival Neoplasms; Drug Eruptions; | 2019 |
Identification of miR-29c and its Target FBXO31 as a Key Regulatory Mechanism in Esophageal Cancer Chemoresistance: Functional Validation and Clinical Significance.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Esophageal Neoplasms; F-Box Proteins; Fluorouracil | 2019 |
DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Disease-Free | 2013 |
Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2008 |
Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squa | 2011 |
Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Conjunctival Neoplas | 2011 |
Mild clinical phenotype of Kindler syndrome associated with late diagnosis and skin cancer.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Basement Membrane; Blister; Carcinoma, Basal Cell; Cry | 2010 |
Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells.
Topics: Capecitabine; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Comet Assay; Deoxycytidine; D | 2011 |
Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas.
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Female; Flow Cyt | 2011 |
Adjuvant 5-fluorouracil in the treatment of localised ocular surface squamous neoplasia.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Eye Neoplasms; Female; Fluorouracil; Humans; Ma | 2011 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplat | 2010 |
Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetax | 2012 |
Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients.
Topics: Administration, Oral; Adolescent; Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, B | 2013 |
Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Dise | 2003 |
Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 2003 |
Ocular surface squamous neoplasia: a standard of care survey.
Topics: Administration, Topical; Antineoplastic Agents; Biopsy; Combined Modality Therapy; Conjunctival Neop | 2005 |
The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma.
Topics: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Antineoplastic Agents; Combined Modality | 2006 |
Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Density; Bone Matrix; Bone Remode | 2006 |
Retrospective analysis: concurrent chemoradiotherapy using protracted continuous infusion of low-dose cisplatin and 5-fluorouracil for T2N0 glottic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Flu | 2006 |
Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Bromodeoxyuridine; Cell Cycle; Cell Line, Tu | 2008 |